首页> 外文期刊>OncoTargets and therapy >Microwave ablation compared with radiofrequency ablation for treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis
【24h】

Microwave ablation compared with radiofrequency ablation for treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis

机译:微波消融与射频消融治疗肝细胞癌和肝转移的比较:系统评价和荟萃分析

获取原文
           

摘要

Purpose: Percutaneous ablation techniques, including microwave ablation (MWA) and radiofrequency ablation (RFA), have become important minimally invasive treatment options for liver cancer. This systematic review compared MWA with RFA for treatment of liver cancer. Methods: The systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A systematic search of MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials was conducted for randomized and observational studies published from 2006 onwards. A random-effects model was used for meta-analyses and local tumor progression (LTP), technique efficacy, overall survival (OS), disease-free survival (DFS), intrahepatic de novo lesions (IDL), extrahepatic metastases (EHM), length of stay (LOS), and complications were analyzed. Subgroup and sensitivity analyses were also conducted. Results: Of 1379 studies identified, 28 randomized and observational studies met inclusion criteria. The main analysis demonstrated that LTP was significantly reduced by 30% with MWA versus RFA (RR=0.70; P=0.02) (all studies) and by 45% with MWA versus RFA (RR=0.55; P=0.007) (randomized studies only). There were no significant differences between MWA and RFA for other efficacy and safety outcomes. Higher frequency (2450 MHz) and larger tumor size (≥2.5 cm) are amongst variables that may be associated with improved outcomes for MWA. Sensitivity analyses were generally congruent with the main results. Conclusion: MWA is at least as safe and effective as RFA for treating liver cancer and demonstrated significantly reduced LTP rates. Future studies should assess time and costs associated with these two treatment modalities.
机译:目的:包括微波消融(MWA)和射频消融(RFA)在内的经皮消融技术已成为肝癌重要的微创治疗选择。该系统评价将MWA与RFA进行了肝癌治疗比较。方法:系统评价和荟萃分析遵循了系统评价和荟萃分析的首选报告项目(PRISMA)指南。对MEDLINE,EMBASE和Cochrane对照试验中央注册系统进行了系统搜索,以查找2006年以来发表的随机和观察性研究。随机效应模型用于荟萃分析和局部肿瘤进展(LTP),技术疗效,总生存期(OS),无病生存期(DFS),肝内新生病变(IDL),肝外转移(EHM),住院时间(LOS)和并发症进行了分析。还进行了亚组和敏感性分析。结果:在确定的1379项研究中,有28项随机和观察性研究符合纳入标准。主要分析表明,MWA与RFA相比LTP显着降低30%(RR = 0.70; P = 0.02)(所有研究),MWA与RFA相比LTP显着降低45%(RR = 0.55; P = 0.007)(仅随机研究) )。 MWA和RFA在其他功效和安全性结果方面无显着差异。较高的频率(2450 MHz)和较大的肿瘤尺寸(≥2.5cm)是可能与MWA结果改善相关的变量。敏感性分析通常与主要结果一致。结论:MWA在治疗肝癌方面至少与RFA一样安全有效,并证明LTP率显着降低。未来的研究应评估与这两种治疗方式相关的时间和成本。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号